|
| 35263204 | A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. | Leuk Lymphoma | 2023 |
| 37287113 | A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma. | Leuk Lymphoma | 2023 |
| 36965007 | Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. | Am J Hematol | 2023 |
| 36960939 | EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. | Leuk Lymphoma | 2023 |
| 36516082 | Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. | Blood Adv | 2023 |
| 36631449 | Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. | Blood Cancer J | 2023 |
| 34196037 | Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. | Br J Clin Pharmacol | 2022 |
| 35657079 | Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. | N Engl J Med | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 36093297 | Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. | Oncotarget | 2022 |
| 35127183 | Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. | Case Rep Hematol | 2022 |
| 34872103 | Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. | Blood Adv | 2022 |
| 35200084 | Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. | Leuk Lymphoma | 2022 |
| 34570876 | Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. | Blood | 2022 |
| 33210562 | Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. | Leuk Lymphoma | 2021 |
| 33683501 | A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. | Invest New Drugs | 2021 |
| 33504141 | Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. | Haematologica | 2021 |
| 34518841 | Immunogenicity of Pfizer mRNA COVID-19 vaccination followed by J&J adenovirus COVID-19 vaccination in two CLL patients. | medRxiv | 2021 |
| 33089525 | A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. | Eur J Haematol | 2021 |
| 33328591 | Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. | Leukemia | 2021 |
| 32278675 | The First Report of Endoscopic Ultrasound-guided Intralesional Rituximab in a Patient With Mantle Cell Lymphoma Presenting With Isolated Colorectal Involvement. | Clin Lymphoma Myeloma Leuk | 2020 |
| 31177537 | Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. | Br J Haematol | 2019 |
| 29249186 | Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. | Leuk Lymphoma | 2018 |
| 30214788 | Exaggerated arthropod assault: Eosinophilic dermatosis in a patient with small lymphocytic lymphoma. | Clin Case Rep | 2018 |
| 29872489 | Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. | Oncotarget | 2018 |
| 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 |
| 29797667 | Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. | Cancer | 2018 |
| 27391978 | Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. | Br J Haematol | 2017 |
| 28487504 | Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. | Am J Case Rep | 2017 |
| 28385778 | Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. | Haematologica | 2017 |
| 28181280 | Identification of targeted therapies for rare adult mature T-cell leukemia using functional ex vivo screening of primary patient samples. | Am J Hematol | 2017 |
| 28838991 | SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. | Haematologica | 2017 |
| 28013106 | CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. | Leuk Res | 2017 |
| 27761930 | Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. | Am J Hematol | 2017 |
| 26968534 | Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. | Blood | 2016 |
| 27582059 | Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. | Sci Transl Med | 2016 |
| 28040733 | Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. | J Natl Cancer Inst | 2016 |
| 26935129 | Cardiac non-Hodgkin's lymphoma: clinical characteristics and trends in survival. | Eur J Haematol | 2016 |
| 26764355 | Postibrutinib outcomes in patients with mantle cell lymphoma. | Blood | 2016 |
| 25146490 | Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(â¿¢) therapeutic protein, for relapsed or refractory NHL patients. | Br J Haematol | 2015 |
| 26425337 | Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. | Ther Adv Hematol | 2015 |
| 26606677 | Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. | PLoS One | 2015 |
| 26254279 | Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. | Oncotarget | 2015 |
| 26231802 | MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting. | Ann Hematol | 2015 |
| 26059948 | Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. | Blood | 2015 |
| 24381226 | A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. | Blood | 2014 |
| 25628989 | Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome. | Leuk Res Rep | 2014 |
| 25441688 | Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event. | Cancer Genet | 2014 |
| 25125625 | Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. | Am J Clin Pathol | 2014 |
| 24615778 | A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). | Blood | 2014 |